Navigation Links
Actavis Launches Generic KADIAN® Capsules in the U.S.
Date:11/11/2011

MORRISTOWN, N.J., Nov. 11, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN®*.

Actavis has been manufacturing KADIAN® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals.  

KADIAN® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.  

Please see full prescribing information at www.actavis.us/morphinesulfate

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

*KADIAN ® is a registered trademark of Actavis Elizabeth LLC.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial succes
'/>"/>

SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actavis Plans Latin America Expansion
2. Actavis Launches Generic Keppra XR® Tablets in the U.S.
3. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
4. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
5. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
6. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
7. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
8. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
9. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
10. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
11. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... company at the Morgan Stanley Global Healthcare Conference in ... Tuesday September 9, 2014 , Presentation time: 5:15 p.m. ... archive of this presentation will be available at http://ir.avanir.com ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing ...
(Date:9/2/2014)... 2014  Edison Nation Medical, the premier healthcare ... American Association for Respiratory Care ( AARC ), ... Edison Nation Medical, which brings 12+ years experience ... their innovation ideas, will work with AARC to ... 50,000 respiratory therapists in bringing their product innovation ...
(Date:9/2/2014)... Today, Analysts Review released its ... ), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR ), ... (NYSE: SNY ) and GlaxoSmithKline plc (NYSE: ... publication. To reserve complementary membership, limited openings are available ... Reports ,WellPoint Inc. (WellPoint) posted on the Events and ...
Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... Operators in the Community Services industry ... arranging care and counsel for those in need. In ... to derive $39.4 billion in revenue, which includes a ... the five years through 2014-15, the subdivision is forecast ... growth of 4.1% in 2014-15. , As the population ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. ... with weight loss by blocking a certain nerve linked to ... among obese patients. Using electric impulses to block the ... hoped to suppress feelings of hunger. And, they did, just ... safely blocks the nerve that connects the brain to the ...
(Date:9/2/2014)... LEBANON, NH Doctors trained in locations with less ... better at making clinical decisions that spare patients unnecessary ... in JAMA Internal Medicine . , "Growing concern ... spurred interest in assessing physicians, ability to avoid the ... of the VA Outcomes Group and The Dartmouth Institute ...
(Date:9/2/2014)... GA (PRWEB) September 02, 2014 Last year, ... new level with the launch of a luxurious line of ... announce that the SEA ISLAND COTTON Socks are joining the ... level, giving more people the comfort of natural cotton fibers. ... Socks, they are surprised to find socks as soft as ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2
... ETT assessment is used to diagnose diseases, ... achalasia. These studies are commonly performed in ... the use of ionizing radiation and catheters, ... Recently, several types of assessments were performed ...
... question whether a common European position on advance directives, ... was discussed at a recent workshop organised by the ... allows people to specify how they would like their ... living will is supposed to determine what medical treatment ...
... Impact of McCain, Obama,Proposals, WASHINGTON, Oct. 31 ... and costs are continuing to skyrocket --,making health care ... United States., A detailed analysis of each candidate,s ... government is included in the Guide to,Healthcare: The 2008 ...
... Wolters Kluwer, a,market leading global information services and ... of Robert Becker to the,position of President and ... Becker is currently CEO of Wolters Kluwer Law ... CEO of Wolters Kluwer Law &,Business (U.S.)., ...
... National Plan to Make LTC Affordable, NEW YORK, ... care (LTC) financing stands to undermine our family care,giving ... up with a,solution, a panel of speakers said today ... forum featured national and state policy experts discussing,different potential ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... Arcapita Inc. and Health Care REIT (HCN), under,which HCN ... owning 29 senior,housing properties managed by Sunrise, has been ... on Sunrise,s 10% interest in the,venture. Sunrise will continue ...
Cached Medicine News:Health News:A biomagnetic diagnostic technique to evaluate esophageal transit time 2Health News:Europe seeks consensus over 'living wills' 2Health News:Europe seeks consensus over 'living wills' 3Health News:Candidates' Proposals to Address Health Care Cost, Coverage and Quality Come at Major Costs 2Health News:Candidates' Proposals to Address Health Care Cost, Coverage and Quality Come at Major Costs 3Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 2Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 3Health News:Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.) 4Health News:State and National Leaders Call for Long-term Care Financing Reform 2Health News:State and National Leaders Call for Long-term Care Financing Reform 3Health News:State and National Leaders Call for Long-term Care Financing Reform 4Health News:Sunrise Provides Update on HCN Transaction 2Health News:Sunrise Provides Update on HCN Transaction 3Health News:Sunrise Provides Update on HCN Transaction 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: